The Rising Global Diabetes Epidemic- why a Denmark-based pharmaceutical company is poised for growth.

Marsico Capital Management

Marsico Capital Global Investment insights

On Marsico Capital Management’s trip to Australia in March, Portfolio Managers Tom Marsico and Brandon Geisler highlighted how the firm’s investment process looks to macro trends which serve as a tailwind to inform its fundamental “bottom up” work in finding high quality growth companies for Marsico Capital’s Global Growth portfolio (recently announced as US Institutional Investor's Global Equity Growth Fund of the year). One such example revolves around the demographic trends associated with the growing global diabetes epidemic. Rising obesity rates are one of the reasons diabetes rates continue to rise. In the following pages we want to share why we believe this epidemic will continue to worsen and why Denmark-based pharmaceutical company Novo Nordisk is poised for growth. (VIEW LINK)


Marsico Capital Management
Marsico Capital Management
Marsico Capital Global Investment insights

Marsico Capital Management, LLC (“MCM”) is a Denver, Colorado-based, SEC-registered, investment management firm, Founded by Thomas F. Marsico in 1997. MCM are concentrated growth equity investors where investment ideas most often come from an...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment